A photo of Kavisha Arora.

Instructor, UC Department of Pediatrics


My Biography & Research

Research Interests

Disease-modifying cellular and molecular mechanisms in Cystic Fibrosis and GI-related disorders; airway mucociliary clearance in Cystic Fibrosis

Academic Affiliation

Instructor, UC Department of Pediatrics

Clinical Divisions

Cystic Fibrosis Center, Pulmonary Medicine

Research Divisions

Pulmonary Medicine

My Education

PhD: University of Tennessee Health Science Center, Memphis, TN, 2013.

My Publications

Identification of anoctamin 1 (ANO1) as a key driver of esophageal epithelial proliferation in eosinophilic esophagitis. Vanoni, S; Zeng, C; Marella, S; Uddin, J; Wu, D; Arora, K; Ptaschinski, C; Que, J; Noah, T; Waggoner, L; et al. Journal of Allergy and Clinical Immunology. 2020; 145:239-254.e2.

Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue ΔF508-CFTR. Huang, Y; Arora, K; Mun, KS; Yang, F; Moon, C; Yarlagadda, S; Jegga, A; Weaver, T; Naren, AP. Scientific Reports. 2019; 9.

Patient-derived pancreas-on-a-chip to model cystic fibrosis-related disorders. Mun, KS; Arora, K; Huang, Y; Yang, F; Yarlagadda, S; Ramananda, Y; Abu-El-Haija, M; Palermo, JJ; Appakalai, BN; Nathan, JD; et al. Nature Communications. 2019; 10.

IL-13-induced intestinal secretory epithelial cell antigen passages are required for IgE-mediated food-induced anaphylaxis. Noah, TK; Knoop, KA; McDonald, KG; Gustafsson, JK; Waggoner, L; Vanoni, S; Batie, M; Arora, K; Naren, AP; Wang, Y; et al. Journal of Allergy and Clinical Immunology. 2019; 144:1058-1073.e3.

Solute carrier family 9, subfamily A, member 3 (SLC9A3)/sodium-hydrogen exchanger member 3 (NHE3) dysregulation and dilated intercellular spaces in patients with eosinophilic esophagitis. Zeng, C; Vanoni, S; Wu, D; Caldwell, JM; Wheeler, JC; Arora, K; Noah, TK; Waggoner, L; Besse, JA; Yamani, AN; et al. Journal of Allergy and Clinical Immunology. 2018; 142:1843-1855.

AC6 is the major adenylate cyclase forming a diarrheagenic protein complex with cystic fibrosis transmembrane conductance regulator in cholera. Thomas, A; Ramananda, Y; Mun, K; Naren, AP; Arora, K. Journal of Biological Chemistry. 2018; 293:12949-12959.

Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Harutyunyan, M; Huang, Y; Mun, K; Yang, F; Arora, K; Naren, AP. American Journal of Physiology - Lung Cellular and Molecular Physiology. 2018; 314:L529-L543.

PP-2, a src-kinase inhibitor, is a potential corrector for F508del-CFTR in cystic fibrosis. Wang, Y; Arora, K; Yang, F; Shin, W; Chen, J; Kihara, D; Naren, AP; Jegga, AG. Cold Spring Harbor Laboratory. 2018.

Guanylate cyclase 2C agonism corrects CFTR mutants. Arora, K; Huang, Y; Mun, K; Yarlagadda, S; Sundaram, N; Kessler, MM; Hannig, G; Kurtz, CB; Silos-Santiago, I; Helmrath, M; et al. JCI insight. 2017; 2.

Epithelial Gpr116 regulates pulmonary alveolar homeostasis via Gq/11 signaling. Brown, K; Filuta, A; Ludwig, M; Seuwen, K; Jaros, J; Vidal, S; Arora, K; Naren, AP; Kandasamy, K; Parthasarathi, K; et al. JCI insight. 2017; 2.